Gestational Trophoblastic Disease: Statistics

Approved by the Cancer.Net Editorial Board, 07/2014

ON THIS PAGE: You will find information about how many women are diagnosed with GTD each year. You will also learn some general information on surviving the disease. Remember, survival rates depend on several factors. To see other pages, use the menu on the side of your screen.

Overall, GTD is rare and often curable. In the United States, GTD accounts for less than 1% of all cancers that start in a woman's reproductive system, which is a grouping called gynecologic cancers. GTD occurs in about 1 pregnancy out of every 1,000 U.S. pregnancies. Most of these are HMs. Choriocarcinoma occurs in about 2 to 7 pregnancies out of every 100,000 in the United States. Overall, GTD is more common in other parts of the world, including Asia and Africa.

Nearly all women with an HM or low-risk gestational trophoblastic neoplasia (GTN) can be cured, often with fertility-sparing surgery alone. A placental site trophoblastic tumor can often be cured, particularly if it is found before it spreads outside the uterus. Even with faster-growing GTN, cure rates are as high as 80% to 90%, with intensive treatment.

It is important to remember that statistics on how many women survive this type of disease are an estimate. The estimate comes from data based on women with GTD in the United States each year. So, your own risk may be different. Doctors cannot say for sure how long any woman will live with GTD. Learn more about understanding statistics.

Statistics source: American Cancer Society.

The next section in this guide is Medical Illustrations. It offers drawings of body parts often affected by this disease. Or, use the menu on the left side of your screen to choose another section to continue reading this guide.